Excellence in Pathology and Laboratory Services

Test Update: UroVysion – Bladder Cancer Molecular Detection

Overview ***June 1, 2009***

Associated Pathologists / PathGroup are pleased to announce the addition of UroVysion Bladder Cancer Molecular Detection to our in-house test library. The UroVysion® Bladder Cancer Kit is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from UroVysion are intended for use as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer. AP/PG are on the cutting edge of technology using an automated, FDA-cleared imaging system to further ensure the highest level of quality results.

Methodology: Fluorescence *in situ* hybridization (FISH)

Turnaround Time: 5-7 days

CPT Codes: 88367 (x4)

Specimen Requirements, Shipping and Handling: The UroVysion kit is designed for use on voided urine specimens. Urine is collected at the physician's office **(minimum volume required is 33ml)**, and mixed with Cytolyt preservative. If urine is not shipped immediately after collection, refrigerate and ship via courier within 24 hours. The preferred storage and shipping conditions are on ice packs, but specimens may be stored and shipped at temperatures up to 25°C. Urine specimens must be processed to the point of fixed cell pellets within 72 hours of collection.

Reference Ranges: The normal reference range is Normal FISH.

References:

Package Insert Information:
UroVysion®
Bladder Cancer Kit
(CEP® 3 SpectrumRed™, CEP 7 SpectrumGreen™,
CEP 17 SpectrumAqua™, and
LSI® 9p21 SpectrumGold™)

5/15/2007

For further questions, please contact Client Services at 615-562-9300 or 1-888-474-5227.